It is estimated that persons with diabetes affected by DR and DME in Europe will be up to 8.6 million in 2050, of whom 30% require treatment.[4] Vascular endothelial growth factor (VEGF) is an important factor in the destruction of the blood-retinal barrier, which can lead to blood vessel leakage and macular edema.[5] The level of VEGF in the eyes of DME patients increases, so it is proposed that the use of anti-VEGF (anti-VEGF) drugs may control the process of vision loss or even loss in DME patients. The gene discussed is VEGFA; the disease is diabetes mellitus.